Nandan Kulkarni, Director-India Healthcare at Bernstein believes higher drug prices, supply shortages and a gradual shift in manufacturing to the US could benefit players like Sun Pharma, Lupin and Zydus over the long term. Kulkarni also explains why innovation-led companies are better placed to navigate the changing policy landscape.
